Results 41 to 50 of about 7,028 (198)

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, EarlyView.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Rheumatology and Therapy
Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS ...
Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler   +9 more
doaj   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease [PDF]

, 2020
Background & Aims: We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn’s disease (CD).Methods: We performed a double-blind, phase 2 trial in adults with ...
Ghosh, Subrata, Pangan, Aileen L., Thakkar, Roopal B., Thakkar, Roshni, Feagan, Brian G., Scherl, Ellen, Lewis, James D., D'Haens, Geert, Herfarth, Hans, Colombel, Jean-frederic, Vitale, Lauren, Mohamed, Mohamed-eslam F., Lacerda, Ana P., Schreiber, Stefan, Othman, Ahmed A., Sandborn, William J., Zhou, Qian, Loftus, Edward V., Van Assche, Gert, Panes, Julian, Armuzzi, Alessandro, Huang, Bidan, Peyrin-biroulet, Laurent, D’haens, Geert   +23 more
core   +1 more source

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

RMD Open
Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton’s tyrosine kinase inhibitor ...
Joan T Merrill, Yoshiya Tanaka, Amit Saxena, Xiaofeng Zeng, Martin Aringer, David D’Cruz, Kristin M D’Silva, Ling Cheng, Thao T Doan, Karim R Masri   +9 more
doaj   +1 more source

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Dermatology and Therapy, 2023
Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with AD ...
Norito Katoh, Masanori Ikeda, Yukihiro Ohya, Hiroyuki Murota, Xiaofei Hu, John Liu, Hayato Niiyama, Takuya Sasaki, Eliza M. Raymundo, Hidehisa Saeki   +9 more
doaj   +1 more source

Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)

World Allergy Organization Journal, 2022
Background: Treatment options for adolescents with moderate-to-severe atopic dermatitis (AD) are limited. Oral corticosteroid therapies are used to treat children and adolescents with moderate-to-severe AD; however, long-term use is not recommended ...
Toshiaki Tanaka, MD, Takuya Sasaki, BA, Kimitoshi Ikeda, PhD, Jianzhong Liu, MD, Allan R. Tenorio, MD, Yukihiro Ohya, PhD   +5 more
doaj   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Abrocitinib/upadacitinib eller dupilumab vid måttlig till svår atopisk dermatit? [PDF]

, 2022
Bakgrund: Atopisk dermatit (AD) är en vanlig kronisk inflammatorisk hudsjukdom som kännetecknas av eksematösa vätskande sår och intensiv klåda. AD är dels en T-hjälparcell (TH) - 2 driven sjukdom vilket innefattar den akuta fasen av sjukdomen där TH2 ...
Linde, Paulina
core   +2 more sources

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source